The Medicare Evidence Development & Coverage Advisory Committee looked at the evidence for procedural volume requirements that hospitals and heart-team members currently must meet to perform transcatheter aortic valve replacements versus the prospect of quality measures as a condition of coverage. The discussion at a meeting held this week will inform the US Medicare agency's ongoing reconsideration of its TAVR coverage policy.
A group of Medicare advisors generally supported maintaining procedure-volume requirements for physicians and hospitals as a basis for covering transcatheter aortic valve replacement (TAVR) procedures during a July 25 meeting. But some in the medical and device-maker community argued that the emphasis must shift away from volume and toward quality measures.
The pros and cons of requiring physicians and hospitals to meet minimum annual procedure volumes to receive Medicare reimbursement for...
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
In this week’s Digital Health Roundup, Medtech Insight’s Ryan Nelson highlights Click Therapeutics’ FDA-cleared digital therapeutics (DTx) for depression and Sinaptica Therapeutics’ personalized neuromodulation for Alzheimer’s patients. Marion Webb discusses her interview with MindMaze’s John Krakauer on their gaming-focused DTx to help people recover from serious brain injuries. Elizabeth Orr introduces new voting members of the new Digital Health Advisory Committee and Natasha Barrow discusses Hello Heart’s new symptom-tracking feature in their heart-focused app.
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
Class III devices and panel-track supplements approved by US FDA’s Center for Devices and Radiological Health. Data derived from FDA.gov. Updated weekly.
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
